LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models

BACKGROUND: Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such as enzalutamide as a result. The lysine demethylase LSD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Regufe da Mota, Sergio, Bailey, Sarah, Strivens, Rosemary A., Hayden, Annette L., Douglas, Leon R., Duriez, Patrick J., Borrello, M. Teresa, Benelkebir, Hanae, Ganesan, A., Packham, Graham, Crabb, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941811/
https://www.ncbi.nlm.nih.gov/pubmed/29760584
http://dx.doi.org/10.1186/s12935-018-0568-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941811/
https://www.ncbi.nlm.nih.gov/pubmed/29760584
http://dx.doi.org/10.1186/s12935-018-0568-1

Ejemplares similares